BRIVEST: A ‘real-world’ observational, single-centre study investigating the efficacy, safety and tolerability of Brivaracetam
(2022)
Journal Article
Objective: Via measures of efficacy, tolerability, and safety, this open-label, single-center study assessed the overall effectiveness of Brivaracetam (BRV) for the treatment of epilepsy in the context of ‘real-world’ clinical practice. Methods: Unse... Read More about BRIVEST: A ‘real-world’ observational, single-centre study investigating the efficacy, safety and tolerability of Brivaracetam.